Ardent Health Affirms FY2026 GAAP EPS Guidance of $0.90-$1.27 vs $1.13 Est; Affirms FY2026 Sales Guidance of $6.400B-$6.700B vs $6.567B Est

Benzinga Newsdesk www.benzinga.com Neutral 51.5%

Neg 0% Neu 51.5% Pos 0%

Ardent Health (NYSE:ARDT) affirms FY2026 GAAP EPS guidance from $0.90-$1.27 to $0.90-$1.27 vs $1.13 analyst estimate. Affirms FY2026 sales outlook from $6.400 billion-$6.700 billion to $6.400 billion-$6.700 billion vs $6.567 billion estimate.